The Global mRNA Vaccines Market was valued at USD 6.2 billion in 2025 and is estimated to grow at a CAGR of 2.8% to reach USD 7.2 billion by 2035.
The market is expected to recover steadily as mRNA technology continues gaining acceptance across a wider range of healthcare applications. Increasing research activity in infectious disease prevention, therapeutic applications, regenerative medicine, and next-generation vaccine development is creating new growth opportunities. Advancements in mRNA delivery systems, lipid nanoparticle (LNP) technologies, and manufacturing capabilities are further improving the scalability and effectiveness of these vaccines. mRNA vaccines work by using messenger RNA molecules to guide cells in producing specific antigens that trigger immune responses against targeted conditions. Their ability to support rapid development, adaptable manufacturing processes, and scalable production has positioned mRNA technology as a significant innovation platform within modern vaccine development. These advantages continue to encourage broader exploration of mRNA-based solutions beyond traditional vaccine applications.
The comirnaty segment held a 70% share in 2025. Despite the decline in overall COVID-19 vaccine demand, Comirnaty has maintained market leadership due to its established global distribution network, continued regulatory acceptance, and ongoing utilization in vaccination programs. The product benefits from its early market entry, extensive approval history, and availability across major healthcare markets. Continued confidence in its effectiveness, safety profile, and use among priority populations has supported its sustained demand through seasonal vaccination initiatives.
The government immunization programs segment held 63.2% share in 2025 and is projected to reach USD 4.2 billion during 2026-2035. Public health agencies continue to play a critical role in supporting mRNA vaccine adoption through funding, procurement activities, and large-scale distribution programs. Government-led vaccination initiatives remain essential for maintaining coverage among vulnerable groups and supporting seasonal immunization campaigns. International health collaborations and public sector efforts to improve vaccine availability have also strengthened supply networks and supported the continued importance of government immunization programs within the market.
North America mRNA Vaccines Market accounted for 45.3% share in 2025. The region maintains a strong position due to the presence of major biotechnology and pharmaceutical companies involved in mRNA research, development, and commercialization. Continued investments in advanced research infrastructure, clinical development programs, and manufacturing capabilities are supporting the creation of next-generation mRNA vaccines and therapeutic solutions. The region’s strong innovation ecosystem and established healthcare infrastructure continue to contribute significantly to market growth.
Prominent players operating in the global mRNA vaccines market include global companies such as Pfizer, BioNTech, and Moderna, along with pipeline-focused companies including Daiichi Sankyo, Ethris, Meiji Seika Pharma, Arcturus Therapeutics, Sanofi, Providence Therapeutics, Strand Therapeutics, and Orna Therapeutics. Companies operating in the mRNA vaccines market are strengthening their market presence through continuous research and development, strategic collaborations, pipeline expansion, and investments in advanced manufacturing capabilities. Key industry participants are focusing on improving mRNA delivery technologies, enhancing vaccine stability, and developing new applications beyond infectious disease prevention. Companies are also expanding clinical trial programs, forming research partnerships, and increasing production capacity to support future demand. Strategic licensing agreements, technology collaborations, and investments in next-generation platforms are helping businesses accelerate innovation and strengthen competitive positioning.
This product will be delivered within 2-4 business days.
The market is expected to recover steadily as mRNA technology continues gaining acceptance across a wider range of healthcare applications. Increasing research activity in infectious disease prevention, therapeutic applications, regenerative medicine, and next-generation vaccine development is creating new growth opportunities. Advancements in mRNA delivery systems, lipid nanoparticle (LNP) technologies, and manufacturing capabilities are further improving the scalability and effectiveness of these vaccines. mRNA vaccines work by using messenger RNA molecules to guide cells in producing specific antigens that trigger immune responses against targeted conditions. Their ability to support rapid development, adaptable manufacturing processes, and scalable production has positioned mRNA technology as a significant innovation platform within modern vaccine development. These advantages continue to encourage broader exploration of mRNA-based solutions beyond traditional vaccine applications.
The comirnaty segment held a 70% share in 2025. Despite the decline in overall COVID-19 vaccine demand, Comirnaty has maintained market leadership due to its established global distribution network, continued regulatory acceptance, and ongoing utilization in vaccination programs. The product benefits from its early market entry, extensive approval history, and availability across major healthcare markets. Continued confidence in its effectiveness, safety profile, and use among priority populations has supported its sustained demand through seasonal vaccination initiatives.
The government immunization programs segment held 63.2% share in 2025 and is projected to reach USD 4.2 billion during 2026-2035. Public health agencies continue to play a critical role in supporting mRNA vaccine adoption through funding, procurement activities, and large-scale distribution programs. Government-led vaccination initiatives remain essential for maintaining coverage among vulnerable groups and supporting seasonal immunization campaigns. International health collaborations and public sector efforts to improve vaccine availability have also strengthened supply networks and supported the continued importance of government immunization programs within the market.
North America mRNA Vaccines Market accounted for 45.3% share in 2025. The region maintains a strong position due to the presence of major biotechnology and pharmaceutical companies involved in mRNA research, development, and commercialization. Continued investments in advanced research infrastructure, clinical development programs, and manufacturing capabilities are supporting the creation of next-generation mRNA vaccines and therapeutic solutions. The region’s strong innovation ecosystem and established healthcare infrastructure continue to contribute significantly to market growth.
Prominent players operating in the global mRNA vaccines market include global companies such as Pfizer, BioNTech, and Moderna, along with pipeline-focused companies including Daiichi Sankyo, Ethris, Meiji Seika Pharma, Arcturus Therapeutics, Sanofi, Providence Therapeutics, Strand Therapeutics, and Orna Therapeutics. Companies operating in the mRNA vaccines market are strengthening their market presence through continuous research and development, strategic collaborations, pipeline expansion, and investments in advanced manufacturing capabilities. Key industry participants are focusing on improving mRNA delivery technologies, enhancing vaccine stability, and developing new applications beyond infectious disease prevention. Companies are also expanding clinical trial programs, forming research partnerships, and increasing production capacity to support future demand. Strategic licensing agreements, technology collaborations, and investments in next-generation platforms are helping businesses accelerate innovation and strengthen competitive positioning.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Patient, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- Pfizer
- BioNTech
- Moderna
- Daiichi Sankyo
- Ethris
- Meiji Seika Pharma
- Arcturus Therapeutics
- Sanofi
- Providence Therapeutics
- Strand Therapeutics
- Orna Therapeutics
